SPRO
Spero Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.21
−0.82%Margins
Gross margin
100.0%
EBITDA margin
17.9%
EBIT margin
14.0%
Net margin
17.2%
FCF margin
45.6%
16.7%
Return on equity
14.0%
Return on assets
13.0%
Return on invested capital
0.77x
Asset turnover
$19.6M
Cash from operations
$0.87
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026